New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 20, 2014
09:40 EDTEXELSummer Street's chief scientific officer holds analyst/industry conference call
Chief Science Officer Classen discusses Exelixis' Cabozantinib for treatment of mestastatic prostate cancer on an Analyst/Industry conference call to be held on March 20 at 10 am.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
16:41 EDTEXELExelixis sees first six months operating expenses $70M-$80M
Subscribe for More Information
16:40 EDTEXELExelixis reports Q1 EPS (18c), consensus (24c)
Reports Q1 revenue $9.39M, consensus $8.08M.
April 20, 2015
07:20 EDTEXELAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use